Company Filing History:
Years Active: 1989
Title: Ren-Tui Teng: Innovator in Radioligand Development
Introduction
Ren-Tui Teng is a notable inventor based in Upton, NY (US). He has made significant contributions to the field of radioligands, particularly in the development of compounds that enhance the study of dopamine receptors in the human brain. His work is crucial for advancing medical imaging techniques and understanding neurological conditions.
Latest Patents
Ren-Tui Teng holds a patent for "No-carrier-added [.sup.18 F]-N-fluoroalkylspiroperidols." This patent discloses radioligands labeled with the positron-emitting radionuclide [.sup.18 F], which are suitable for dynamic studies in living humans using positron emission tomography. The new [.sup.18 F]-N-fluoroalkylspiroperidols, characterized by an alkyl group containing 2-6 carbon atoms, exhibit an extremely high affinity for dopamine receptors. These compounds provide enhanced uptake and retention in the brain while reducing radiation burden. The patent also includes a new synthetic procedure for these radioligands and a method for preparing the radiolabeled alkyl halide alkylating reagents.
Career Highlights
Ren-Tui Teng is associated with the United States of America as represented by the United States. His innovative work in the field of radioligands has positioned him as a key figure in advancing medical imaging and understanding brain function.
Collaborations
Ren-Tui Teng has collaborated with notable colleagues, including Chyng-Yann Shiue and Alfred P Wolf. These collaborations have contributed to the development of groundbreaking technologies in the field of radioligands.
Conclusion
Ren-Tui Teng's contributions to the field of radioligands are invaluable for both medical research and clinical applications. His innovative work continues to pave the way for advancements in understanding and treating neurological disorders.